Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 4/20 | 0.47 |
| ▸ | AURKA | O14965 | 2/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.45 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.44 |
| ▸ | ACKR3 | P25106 | 15/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30183779 | 0.99 | CDK2 (0.46) | CDK2AURKACCNA2CCNA1CDK5 | |
| SCHEMBL30183523 | 0.92 | CDK2 (0.45) | CDK2AURKACCNA2CCNA1CDK5 | |
| SCHEMBL20649161 | 0.92 | CDK2 (0.45) | CDK2AURKACCNA2CCNA1CDK5 | |
| SCHEMBL20649117 | 0.92 | CDK2 (0.45) | CDK2AURKACCNA2CCNA1 | |
| SCHEMBL21875690 | 0.92 | ACKR3 (0.46) | CDK2AURKACCNA2CCNA1CDK5 | |
| Hydrochloric Acid SCHEMBL30183950 | 0.91 | CDK2 (0.44) | CDK2AURKACCNA2CCNA1 | |
| SCHEMBL30183148 | 0.91 | CDK5 (0.45) | CDK2AURKACCNA2CCNA1CDK5 | |
| SCHEMBL20649121 | 0.91 | CDK5 (0.45) | CDK2AURKACCNA2CCNA1CDK5 | |
| SCHEMBL20649150 | 0.90 | CDK2 (0.44) | CDK2AURKACCNA2CCNA1CDK5 | |
| SCHEMBL30183347 | 0.90 | CDK2 (0.44) | CDK2AURKACCNA2CCNA1CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11117901-B2 | Substituted pyrazolo[4,3-h]quinazolines as choline kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2021-09-14 | — | — | US | disclosed |
| US-20200131188-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES AS CHOLINE KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2020-04-30 | — | — | US | disclosed |
| WO-2019011715-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES AS CHOLINE KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131188-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES AS CHOLINE KINASE INHIBITORS | CHKA, CHKB, NADK | CDK2 306/4885AURKA 141/4885CCNA2 2088/4885 |
| US-11117901-B2 | Substituted pyrazolo[4,3-h]quinazolines as choline kinase inhibitors | CHKA, CHKB, NADK | CDK2 319/4885AURKA 210/4885CCNA2 1881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.